Register here!

Since the inaugural Congress in 2001, this meeting has become the premier forum for discussion on the latest advances in myeloproliferative neoplasms (MPNs). This year, the Congress will focus on timely topics of interest to hematologists and oncologists who treat patients with these rare disorders.

The Congress program format will utilize case presentations to highlight the essential features of MPN pathophysiology, diagnosis and management, as well as the roles of next generation sequencing and the MPN driver mutation and allele burden in clinical decision making. In addition to defining the role of pegylated interferon and its long-acting derivatives in MPN therapy, the role of immunotherapy in the MPNs and novel agents for MPN treatment will be reviewed.

New this year will be a discussion of the management of accelerated and blast phase MPN, patient selection for bone marrow transplantation, and how to integrate MPN patient symptom scores with therapeutic planning.

Congress attendees will have the opportunity to participate in a variety of educational formats including didactic sessions, case reviews, poster sessions and oral abstract presentations, as well as multiple networking and one-on-one discussion opportunities. To allow more time for participant questions, time has also been allotted for a panel discussion with Congress faculty.

TARGET AUDIENCE:

The 12th International Congress on MPNs is specifically designed for hematologists, medical oncologists, and other healthcare professionals (physicians, clinicians, physicians-in-training, oncology nurses, pharmacists, physician assistants, etc.) involved and/or interested in the therapeutic management of patients with myeloproliferative neoplasms and chronic myeloid leukemia.

EDUCATIONAL OBJECTIVES:
After participating in this program, participants should be able to:

1. Describe underlying molecular and genetic events involved in MPNs and how these events could be utilized in the clinic.
2. Discuss the role and utilization of current approved therapies in MPNs, as well as the potential role of agents in development.
3. Assess how to manage symptoms and therapy-associated adverse events for patients with MPNs.
4. Outline the current treatment strategies (including treatment termination) for patients with chronic myeloid leukemia (CML).